Athanor Capital, LP Kodiak Sciences Inc. Transaction History

Athanor Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$110.45 - $164.47 $561,306 - $835,836	-5,082 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$60.78 - $154.03 $292,108 - $740,268	-4,806 Reduced 48.6%	5,082 $747,000
Q3 2020 Nov 16, 2020	SELL	$45.05 - $59.27 $179,884 - $236,665	-3,993 Reduced 28.77%	9,888 $585,000
Q2 2020 Aug 13, 2020	BUY	$42.74 - $66.25 $593,273 - $919,616	13,881 New	13,881 $751,000
Q1 2020 May 14, 2020	SELL	$38.18 - $73.95 $687,240 - $1.33 Million	-18,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$13.9 - $76.65 $250,200 - $1.38 Million	18,000 New	18,000 $1.3 Million

101

38.8M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $289M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.